UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 15, 2012

 

 

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware		001-33057		76-0837053
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
355 Alhambra Circle Suite 1500 Coral Gables, Florida				33134
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 8.01

Other Events

On November 15, 2012, the Company issued a press release announcing its financial and operational results for the three and nine months ended September 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits

 

99.1

Press release issued by the Company on November 15, 2012

 

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 15, 2012

 

3

Exhibit 99.1

 

 

NEWS RELEASE		FOR IMMEDIATE RELEASE
For Further Information Contact:
Patrick J. McEnany		Melody Carey
Catalyst Pharmaceutical Partners		Rx Communications Group
Chief Executive Officer		Co-President
(305) 529-2522		(917) 322-2571
pmcenany@catalystpharma.com		mcarey@rxir.com

Catalyst Pharmaceutical Partners Announces

Third Quarter 2012 Financial Results

CORAL GABLES, FL, November 15, 2012 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced its financial results for the third quarter and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $2,621,535, or $0.08 per basic and diluted share, compared to a net loss of $1,127,841, or $0.05 per basic and diluted share, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $3,999,801, or $0.14 per basic and diluted share, compared to a net loss of $4,039,128, or $0.19 per basic and diluted share, for the same period in 2011. These fluctuations were primarily due to non-cash changes in the fair value of the Company’s outstanding warrants liability, which resulted in losses from the change in fair value of warrants liability of $1,340,566 and $289,440, respectively, for the three and nine months ended September 30, 2012.

Research and development expenses for the third quarter of 2012 were $654,837, compared to $614,137 in the third quarter of 2011. Research and development expenses for the nine months ended September 30, 2012 were $1,914,905 compared to $2,423,725 for the first nine months of 2011. During the nine month period ended September 30, 2012, research and development expenses decreased when compared to the same period in 2011, as expenses incurred during the nine month period ended September 30, 2011 included pre-clinical studies and drug development activities for CPP-115 in connection with the submission of an IND for CPP-115 (which occurred during the fourth quarter of 2011). General and administrative expenses for the third quarter of 2012 totaled $628,876, compared to $516,873 in the third quarter of 2011. General and administrative expenses for the first nine months of 2012 totaled $1,800,882 compared to $1,623,998 in the first nine months of 2011.

As a development-stage specialty pharmaceutical company, Catalyst had no revenues in either the third quarter of 2012 or the first nine months of 2012.

At September 30, 2012, the Company had cash and cash equivalents of $12.0 million and no debt. On October 26, 2012, the Company received a $5 million cash infusion from BioMarin. Catalyst believes that its existing cash and cash equivalents will be sufficient to support its operations through the first quarter of 2014.

---

Recent Events

 

•

Closed a registered direct public offering with net proceeds of approximately $5.6 million in August 2012

 

•

Announced on September 24, 2012 that an investigator-sponsored CPP-109 Tourette’s Disorder proof-of-concept study was initiated

 

•

Announced on October 31, 2012 that Catalyst entered into a strategic collaboration with BioMarin for Firdapse™ in North America. In connection with such collaboration, BioMarin invested $5 million in Catalyst, which will be used for the development of Firdapse™

 

•

Reported unsuccessful top-line results for the CPP-109 Phase II(b) clinical trial on November 8, 2012

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system. Catalyst has three products in development, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor), which Catalyst plans to develop for the treatment of cocaine addiction and Tourette’s Disorder, CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g. , visual field defects, or VFDs) from those associated with vigabatrin, which Catalyst plans to develop for the treatment of drug addiction and epilepsy (primarily infantile spasms) and Firdapse™, which Catalyst plans to develop for commercialization in North America as a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS). For additional information about Catalyst, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-109 will be determined to be an effective treatment for cocaine addiction and Tourette’s Disorder, whether CPP-115 will be determined to be an effective treatment for its targeted indications, whether Firdapse™ will be determined to be an effective treatment for LEMS or other diseases, whether Catalyst will ever receive an approval of an NDA for any of its product candidates, whether Catalyst will ever be in a position to commercialize any of its product candidates, and those other factors described in Catalyst’s filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the forward-looking statements contained in this press release. Copies of the Company’s filings with the SEC are available from the SEC, may be found on Catalyst’s web site or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

 

Page 2

---

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS (unaudited)

 

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2012				2011				2012				2011
Revenues		$	—			$	—			$	—			$	—
Operating costs and expenses:
Research and development			654,837				614,137				1,914,905				2,423,725
General and administrative			628,876				516,873				1,800,882				1,623,998
Total operating costs and expenses			1,283,713				1,131,010				3,715,787				4,047,723
Loss from operations			(1,283,713	)			(1,131,010	)			(3,715,787	)			(4,047,723	)
Interest income			2,744				3,169				5,426				8,595
Change in fair value of warrants liability			(1,340,566	)			—				(289,440	)			—
Loss before income taxes			(2,621,535	)			(1,127,841	)			(3,999,801	)			(4,039,128	)
Provision for income taxes			—				—				—				—
Net loss		$	(2,621,535	)		$	(1,127,841	)		$	(3,999,801	)		$	(4,039,128	)
Loss per share – basic and diluted		$	(0.08	)		$	(0.05	)		$	(0.14	)		$	(0.19	)
Weighted average shares outstanding – basic and diluted			32,132,824				21,654,680				27,913,800				21,083,485

 

Page 3

---

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED BALANCE SHEETS

 

		September 30, 2012				December 31, 2011
		(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents		$	11,973,860			$	6,029,067
Prepaid expenses			111,632				199,116
Total current assets			12,085,492				6,228,183
Property and equipment, net			10,832				12,186
Deposits			8,888				8,888
Total assets		$	12,105,212			$	6,249,257
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	355,909			$	263,934
Accrued expenses and other liabilities			397,421				569,867
Total current liabilities			753,330				833,801
Accrued expenses and other liabilities, non-current			22,285				9,518
Warrants liability, at fair value			1,934,680				1,645,240
Total liabilities			2,710,295				2,488,559
Total stockholders’ equity			9,394,917				3,760,698
Total liabilities and stockholders’ equity		$	12,105,212			$	6,249,257

 

Page 4